Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SAR341402
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 16, 2019
Lead Product(s) : SAR341402
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2019
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 04, 2019
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2019
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2018
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 19, 2018
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2018
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAR425899
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2018
Lead Product(s) : SAR425899
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2018
Lead Product(s) : Sotagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAR425899
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2017
Lead Product(s) : SAR425899
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
